Docétaxel : interactions médicamenteuses
Docétaxel (Taxotere, Docivyx) présente 126 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 64 de niveau majeur, 1 de niveau modéré, 61 de niveau mineur et 0 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.
Interactions d'après la notice
Interactions majeures (64)
The alcohol content in a dose of Docetaxel Injection may affect the central nervous system and should be taken into account for patients in whom alcohol intake should be avoided or minimized. (notice Docétaxel, Mises en garde et précautions)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)
Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)
Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)
Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)
Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)
Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)
Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)
Severe hypersensitivity reactions have been reported in patients despite dexamethasone premedication. (notice Docétaxel, Mise en garde encadrée)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)
Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)
Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)
Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)
Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)
Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)
- PaclitaxelMajeure
Patients who have previously experienced a hypersensitivity reaction to paclitaxel may develop a hypersensitivity reaction to docetaxel that may include severe or fatal reactions such as anaphylaxis. (notice Docétaxel, Mises en garde et précautions)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)
Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (notice Docétaxel, Interactions médicamenteuses)
Interactions modérées (1)
- TrastuzumabModérée
In BCIRG006, a total of 2.9% (31/1056) of patients in the TCH (docetaxel, carboplatin, trastuzumab) arm (1.5% during the chemotherapy phase and 1.4% during the monotherapy phase) and 5.7% (61/1068) of patients in the AC-TH arm (1.5% during the chemotherapy phase and 4.2% during the monotherapy phase) discontinued trastuzumab due to cardiac toxicity. (notice Trastuzumab, Mises en garde et précautions)
Mentions mineures (61)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
In the 251 patients with metastatic breast cancer who received XELODA with docetaxel, 68% had grade 3 or 4 neutropenia, 2.8% had grade 3 or 4 thrombocytopenia, and 10% had grade 3 or 4 anemia. (notice Capécitabine, Mises en garde et précautions)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
- CisplatineMineure
In gastric cancer patients treated with docetaxel in combination with cisplatin and fluorouracil (TCF), febrile neutropenia and/or neutropenic infection occurred in 12% of patients receiving G-CSF compared to 28% who did not. (notice Docétaxel, Mises en garde et précautions)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
Treatment-related AML or MDS has occurred in patients given anthracyclines and/or cyclophosphamide, including use in adjuvant therapy for breast cancer. (notice Docétaxel, Mises en garde et précautions)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
- DoxorubicineMineure
In the adjuvant breast cancer trial (TAX316) AML occurred in 3 of 744 patients who received docetaxel, doxorubicin, and cyclophosphamide (TAC) and in 1 of 736 patients who received fluorouracil, doxorubicin, and cyclophosphamide [ see Clinical Studies (14.2) ]. (notice Docétaxel, Mises en garde et précautions)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
In gastric cancer patients treated with docetaxel in combination with cisplatin and fluorouracil (TCF), febrile neutropenia and/or neutropenic infection occurred in 12% of patients receiving G-CSF compared to 28% who did not. (notice Docétaxel, Mises en garde et précautions)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
- Olmésartan, amlodipine et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Mineure
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (notice Docétaxel, Interactions médicamenteuses)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)
Vérifiez Docétaxel avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.
Ouvrir dans le vérificateurCeci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.